The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to Aflibercept
Not Applicable
- Conditions
- Exudative Age-related Macular Degeneration
- Registration Number
- JPRN-UMIN000012724
- Lead Sponsor
- Department of Ophthalmology, Kagawa university faculty of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2)Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3)Prior treatment with photodynamic therapy 4)Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5)Active intraocular inflammation 6)Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7)Patient who the doctor in charge judges are ineligible for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method